Two cancer immunotherapy drugs, nivolumab and Keytruda, proved remarkably effective against the blood cancer Hodgkin lymphoma in two small, separate studies. The studies add to growing evidence of the potential for enlisting the immune system in the fight against a wide range of tumors. Margaret Shipp, professor of medicine at the Dana Farber Cancer Institute, is a senior co-author of the nivolumab study.
Trending News
Research Provides Clues to Spleen’s Role in Coronary Artery Disease
Genetic variants may drive visible changes in the spleen that contribute to heart disease
Patient Who Received Pig Kidney Becomes First To Progress to Human Kidney Transplant
Study shows xenotransplantation can serve as a bridge for patients with end-stage kidney disease
Pilots, Flight Attendants Have Greater Risk of Radiation-Related Cancer Death Than Other Professions
Findings support efforts to protect U.S. aircrews from cosmic radiation exposure